Andrew Miller
Biopharma Executive and Board Chair | Founder, Karuna Therapeutics and inventor of KarXT/COBENFY | TIME 100 NEXT 2025 | TIME 100 Health Leader | Fierce 50 Honoree
- Role
- Advisor at General Atlantic
- Location
- Boston, MA, US
- LinkedIn followers
- 500 followers
About Andrew Miller
Dr. Andrew Miller is a highly accomplished biopharmaceutical executive with expertise in research and development, company building, capital formation, and corporate strategy. Dr. Miller was named to Time Magazine\'s 100 Next Generation Leaders for 2025 Time Magazine\'s 100 Most Influential People in Health in 2025, and the Fierce 50 of 2025.Most recently, Dr. Miller was the Founder and President of Research and Development at Karuna Therapeutics. Dr. Miller is the lead inventor of Karuna’s KarXT and previously served as Chief Operating Officer, Chief Executive Officer, and as a member of Karuna’s board of directors. Dr. Miller currently serves as the Chairman of the Board at Progentos Therapeutics.Dr. Miller played a lead role in developing KarXT from the initial idea to the approval of COBENFY™ for the treatment of schizophrenia in 2024, as well as building the company from 1 employee to over 350 and raising ~$2B in private and public investor capital prior to the acquisition of Karuna by BMS for $14B in 2024. During his tenure at Karuna, Dr. Miller oversaw clinical development, nonclinical development, regulatory, quality, manufacturing, formulation development, human resources, and corporate development.COBENFY (KarXT) was approved by the U.S. Food and Drug Administration for the treatment of schizophrenia in 2024. KarXT is a first-in-class dual M1/M4 muscarinic acetylcholine receptor agonist, which is thought to mediate benefit to the positive, negative, and cognitive symptoms of schizophrenia. Unlike all previous treatments for schizophrenia, KarXT does not directly block dopamine receptors, and represents the first new class of treatment for schizophrenia in 35 years. COBENFY has received numerous honors, including being a Time Magazine’s invention of the year 2024, one of the 5 biggest medical breakthroughs in 2024 by ABC News, highlighted by the Washington Post as “ something good that happened in 2024, and was one of 13 honorees for the Gizmodo 2025 Science Fair.Dr. Miller has more than 15 years’ experience in the biotech/biopharma industry, previously holding senior and executive-level positions at PureTech Health, Tal Medical, and Entrega Inc. Dr. Miller received his bachelor’s degree in Chemical Engineering from the University of Illinois with highest honors, and his Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology as a Presidential Fellow. Dr. Miller was named to the PharmaVoice 100 and one of the top 40 innovators under 40 by MedTech Boston.
Experience
Advisor
Jan 2025 — Present
Education
Massachusetts Institute of Technology
Doctor of Philosophy (PhD), Chemical Engineering
2003 — 2008
University of Illinois Urbana-Champaign
Bachelor's degree, Chemical Engineering
1999 — 2003
Skills
- Technology Evaluation
- Start-Ups
- Venture Capital
- Pharmaceutical Industry
- Business Strategy
- Deal Sourcing
- Lifesciences
- Licensing
- Commercialization
- Biotechnology
- Corporate Development
- Intellectual Property
- Start-Up Ventures
- Due Diligence
- Entrepreneurship
- Technology Transfer
Find verified contacts for anyone on LinkedIn
Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.
Free plan included · No credit card required
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.